Altis Labs Raises $25M Series A for AI Clinical-Trial Endpoints

Altis Labs announced $25M in Series A financing on September 17, 2026. Altis Labs raised a $25 million Series A co-led by OrbiMed and Qiming Venture Partners USA to expand AI endpoints for oncology clinical trials.

Round details

The financing includes backing from OrbiMed, Qiming Venture Partners USA, Innovation Endeavors, Cancer Breakthrough Fund. The company did not publish a valuation with the announcement.

Round: Series A
Capital announced: $25M
Headquarters: Toronto, Canada

How the company plans to use the capital

Altis will expand its AI models across additional cancer types, scale commercial deployments with biopharmaceutical partners, and work to establish AI endpoints as a standard for oncology trials.

Why this matters for GTM teams

The round points to increasing investment in AI systems that improve trial decisions by connecting medical imaging with longitudinal outcomes and clinical evidence.

Fresh capital is often an operational signal rather than a buying signal by itself. Teams should validate the company’s hiring pattern, product launches, geographic expansion, and technology priorities before choosing the message and timing of outreach.

Source and methodology

This report is based on the company’s announcement and records the disclosed amount, round, investors, location, and stated use of funds. SalesTools Research does not estimate undisclosed valuation or revenue figures.

Primary source: Altis Labs Series A announcement.